Related references
Note: Only part of the references are listed.Functional Characteristics of Two Human MATE Transporters: Kinetics of Cimetidine Transport and Profiles of Iinhibition by Various Compounds
Kin-ya Ohta et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2016)
Modulation of OATP1B-Type Transporter Function Alters Cellular Uptake and Disposition of Platinum Chemotherapeutics
Cynthia S. Lancaster et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2
Jason A. Sprowl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A Re-Evaluation of the Role of hCTR1, the Human High-Affinity Copper Transporter, in Platinum-Drug Entry into Human Cells
Kristin D. Ivy et al.
MOLECULAR PHARMACOLOGY (2013)
Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients
Jing Zhang et al.
FOOD AND CHEMICAL TOXICOLOGY (2012)
Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs)
Anne T. Nies et al.
PLOS ONE (2011)
Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions
Giuliano Ciarimboli et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Protecting Cisplatin-Induced Nephrotoxicity with Cimetidine Does Not Affect Antitumor Activity
Hiromu Katsuda et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2010)
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)
H. Burger et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase
Ryan M. Franke et al.
CLINICAL CANCER RESEARCH (2010)
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
Stephen B. Howell et al.
MOLECULAR PHARMACOLOGY (2010)
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
K. K. Filipski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine
Soichiro Matsushima et al.
DRUG METABOLISM AND DISPOSITION (2009)
Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells
Masahiro Tsuda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Interaction of cisplatin with the human organic cation transporter 2
Kelly K. Filipski et al.
CLINICAL CANCER RESEARCH (2008)
Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications
Hermann Koepsell et al.
PHARMACEUTICAL RESEARCH (2007)
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)
Atsushi Yonezawa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice
Pierre Collinet et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2006)
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants
T Fujita et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?
T Clouse et al.
GYNECOLOGIC ONCOLOGY (2004)
Population pharmacokinetics of cisplatin in adult cancer patients
FE de Jongh et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Molecular and cellular physiology of renal organic cation and anion transport
SH Wright et al.
PHYSIOLOGICAL REVIEWS (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial
JT Santoso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients
FE de Jongh et al.
BRITISH JOURNAL OF CANCER (2003)
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney
Y Urakami et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer
JHM Schellens et al.
ANTI-CANCER DRUGS (2001)
Share Paper
